Kyntra Bio, Inc. (0IL8.L)
ValueMarkers Composite Index
35% below intrinsic value ($11)
Kyntra Bio, Inc. (0IL8.L) — VMCI valuation read
Composite valuation read on 0IL8.L: VMCI 54/100 against a Healthcare sector median of 50. The 4-point above-median print is the headline number for Kyntra Bio, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for 0IL8.L: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on 0IL8.L: 0IL8.L trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 3.0x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
0IL8.L rose 2.3% over the trailing 7 days, with a -18.4% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.